INTRODUCTION
During the past 30 years, the understanding of hepatitis viruses has greatly expanded. Knowledge of hepatitis has progressed from merely describing the various clinical syndromes to a greater understanding of the pathogenesis of disease caused by these viruses and the development of chronic infection that eventually leads to cirrhosis or hepatocellular carcinoma. Expanded understanding also has led to the development of effective vaccines against hepatitis A virus (HAV) and hepatitis B virus (HBV) and antiviral therapies against hepatitis C virus (HCV). The introduction of routine vaccination against HAV and HBV starting in early childhood in the United States has resulted in a substantial decrease in both of these infections in children and the subsequent complications of HBVrelated chronic liver disease. Effective screening of mothers during pregnancy and the administration of HBV vaccine soon after birth, along with administration of hepatitis B immune globulin (HBIG) to infants born to women who have HBV infection, has led to near eradication of perinatally acquired HBV disease in the United States and other countries with effective screening programs. The introduction and routine administration of HAV vaccine in the United States in the 1990s led to near complete elimination of HAV outbreaks among children. Now, antiviral therapies are available for the treatment of chronic HBV and HCV infections. Newer agents are more effective, especially against most genotypes, and cures are frequently observed. In the following review, we summarize the clinical manifestations of these viral infections, the various diagnostic assays that clinicians must know how to order and interpret, therapeutic regimens for HBV and HCV infection, and the various measures used to prevent disease. Table 1 provides a quick review of the important clinical aspects for each virus.
HEPATITIS A

Epidemiology
HAV is a Hepatovirus within the Picornaviridae family. It is a nonenveloped, single-stranded RNA virus. HAV is transmitted via the fecal-oral route. Person-to-person transmission is observed in most cases, but transmission through the consumption of contaminated food or water and even transfusions has been documented. Following ingestion, the virus replicates within the gastrointestinal tract, gaining entry into the liver via the portal venous system. Although the virus appears to be noncytopathic to hepatocytes, inflammation ensues, although chronic liver disease does not occur. Following the incubation period, a large amount of virus is shed in the stool.
The burden of disease throughout the world is greatly influenced by the availability of safe drinking water and uncontaminated food. This is, in large part, dependent on the quality of the sanitary infrastructure. As a result, resource-poor countries and regions often have a higher burden of infection. The improvement of infrastructure and implementation of vaccine programs are 2 key factors that have substantially reduced the burden of HAV infection in many countries. In 2005, the World Health Organization estimated that 126 million cases of HAV infection occurred worldwide, resulting in the death of 35,245 persons. (1) Most infections occur in the community, but hospital-acquired (6)(7) Before the widespread use of HAV vaccination, a disproportionate number of cases occurred among Native American populations. The rate of infection in this group was at least 20 times higher than that in the non-Hispanic white population. At that time, 11 western states were responsible for more than 50% of the cases reported in the United States. Currently, the incidence of HAV infection in the United States is at its lowest. Population-based surveillance collected between 2005 and 2007 estimated an annual incidence rate of 1.3 cases per 100,000 population (range, 0.7-2.3). (8) Before implementation of vaccination programs, the rate of infection was 14 per 100,000 population. More than 90% of affected persons resided in urban areas. Although nearly 50% of all cases occurred in persons ages 15 to 39 years, w20% of cases were among those younger than age 15 years. Increased disease susceptibility has now shifted to older age groups in whom morbidity and mortality rates are greater. (8) Travel remains a key risk factor for the acquisition of HAV infection. International travel was found to be a risk factor in 45% of reported cases. Contact with a case was a risk factor in w15% of cases. Of interest, 24% of reported cases had been in contact with a traveler but had not travelled themselves. To minimize this source, vaccination of susceptible individuals prior to travel is imperative. (9) Although there is a single HAV serotype, various genotypes and subgenotypes have been identified. Subtyping has been found to be useful in outbreak investigations because various HAV genotypes circulate throughout the world. Genotype 1A is responsible for most infections within the United States and most of Latin America, whereas 1B is almost exclusively observed in Brazil.
Clinical Features
HAV infection is a self-limited infection of the liver. The average incubation period is w30 days (range, 15-50 days). Most infections in children (>70%) are asymptomatic or of mild severity. Asymptomatic infection was observed in 13.6% of children, and subclinical disease was observed in 18.6% of children. Approximately 15% of children with HAV infection have atypical manifestations of the disease.
Fever, abdominal pain, nausea, fatigue, loss of appetite, and jaundice are common features in the symptomatic child. Symptomatic HAV infection is rarely observed among infants and children younger than age 6 years, with fewer than 10% having jaundice. (10) In those younger than age 3 years, anicteric infection is 17 times more common than icteric infection. In a cohort of 118 children whose mean age was 8.6 years, jaundice was observed in only 48.3%. (11) Cholestasis, acute liver failure, relapsing hepatitis, ascites, and hematologic problems (autoimmune hemolytic anemia, aplastic anemia, and pure red cell aplasia) are described. In addition, pleural and pericardial effusion, acute kidney injury (AKI), pancreatitis, and acute reactive arthritis are reported in children and adults. (12) Approximately 80% of adults infected with HAV may develop severe hepatitis. (12) HAV does not usually cause chronic disease. However, some children with protracted jaundice have liver histology suggestive of chronic liver disease. (13) Fulminant hepatitis is rare, with a reported incidence of less than 1%. In a study from Pakistan, 56% of children with fulminant hepatic failure had HAV infection compared with 18% who had HBV infection. (14) Young age, encephalopathy, severe coagulopathy, and low transaminases are markers of severe disease and poor outcomes. In a study of patients with HAV infection, w8% developed concomitant AKI. (15) In another study, 7% of patients had AKI. (16) Fulminant hepatitis, leukocytosis, and elevated C-reactive protein were independent markers for risk. A fatal case of encephalitis has been described in an 11-year-old girl presenting with seizures, coma, and anicteric hepatitis. (15)(17)
Diagnostic Testing
Detection of HAV-specific antibodies (anti-HAV immunoglobulin [Ig]G and IgM) is the most common method for diagnosing HAV infections (Table 2) . Anti-HAV IgM antibodies appear within 5 to 10 days after symptom onset and may persist for up to 4 months. Anti-HAV IgG titers tend to rise later but persist for a longer duration. Most patients with HAV infections develop anti-HAV IgM antibodies at the end of the incubation period (w4 weeks) and with the onset of symptoms. However, w11% of patients in 1 study had a negative IgM at the time of presentation. Although HAV IgM is the diagnostic test for acute HAV infection, clinicians must keep in mind potential negative results when evaluating children in the early phases of the disease. 
Treatment
There is no available antiviral treatment for HAV. Management is largely supportive.
Prevention
HAV vaccine is routinely administered to children in the United States as a 2-dose series starting at age 1 year (Table  3) . HAV vaccine is also recommended for all susceptible travelers to countries that have a high prevalence of HAV infection. (20) Some adolescents may require pretravel vaccination if they have not been vaccinated against HAV. In spite of this recommendation and because of lack of awareness among some older travelers, HAV vaccine is often not received before travel to high-risk areas. SubSaharan Africa and south Asia have high endemicity levels and almost no susceptible adolescents and adults because most infections occur early in life. (21) Vaccination rates in adolescents remain low because catch-up vaccination has not been completely implemented.
HAV vaccination programs in Native American communities in the United States led to a 20-fold decrease in the number of HAV cases. (22) In Israel, a substantial effect of vaccination was observed in children younger than age 5 years, with a reduction from 239.4 cases per 100,000 in Screening for HAV performed at an international adoption center determined that 29% of children had evidence of infection. (29) One percent of children were found to have acute infection (positive IgM). Children born in Africa had the highest prevalence of infection (72%) and children adopted from the Asia/Pacific Rim had the lowest prevalence (17%). In a systematic review of published studies, the protective effects of HAV vaccine was observed for up to 15 years after vaccination, (30) Immunocompromised persons should also receive HAV vaccination. Approximately 75% subsequently develop antibodies, but the robustness of this response is influenced by the degree and type of immunosuppression. Tumor necrosis factor-a blocker recipients appear to respond better than other individuals, with 92% developing good serologic response. Only 69% of persons receiving regimens consisting of methotrexate and azathioprine with or without corticosteroids responded to the vaccine. (33) Because of the variability of immune responses, obtaining an antibody titer after completion of the vaccine series appears reasonable.
Before the licensing of HAV vaccines, protection for susceptible individuals (pre-and postexposure) was achieved through intramuscular administration of human immune globulin (Table 4) . Unfortunately, protection was shortlived and only partially protective in some individuals. Travelers expecting prolonged stays in high-risk regions or individuals expecting prolonged or frequent exposures require readministration every 3 to 5 months.
Studies have demonstrated that HAV is immunogenic in infants younger than age 1 year who are born to seronegative mothers. (34)(35)(36) Maternal antibodies appear to blunt the immune response to the vaccine. Although still greater than concentrations considered to be protective, postvaccination antibody values in infants born to seropositive mothers were lower than those in infants born to seronegative mothers. (37) HAV vaccine has not been approved by the Food and Drug Administration (FDA) for use in children younger than age 1 year. Unimmunized and susceptible individuals exposed to HAV and at risk for infection benefit from postexposure HAV vaccination or immune globulin. (38) However, finding immune globulin in the United States has become difficult.
HEPATITIS B
Epidemiology
HBV is a pro-oncogenic, noncytotoxic, enveloped circular DNA hepadnavirus infrequently responsible for chronic infection in developed countries. Mother-to-child transmission is responsible for at least one-third of all CHB disease worldwide. (41) The risk of perinatal infection is greatest (90%) when a mother becomes acutely infected during the third trimester and demonstrates antigenemia with both HBV surface antigen (HBsAg) and HBV envelope antigen (HBeAg), with HBeAg being a marker for higher infectivity. Approximately 65% of children born to HBeAg-positive mothers develop chronic infection compared to only w28% of those born to HBeAg-negative mothers. (42) Not surprisingly, the risk of infection is related to the magnitude of endemicity. In addition, not surprisingly, mothers with high HBV DNA values and who deliver vaginally are more likely to infect their infants at birth. (43) Progress to CHB is related to the timing of acute infection, with the greatest risk (90%) conferred on those infected before their first birthdays. The risk of CHB declines substantially with age, peaking at 50% of those infected between ages 1 and 5 years and 1 in 10 of those infected thereafter. According to a recent study, perinatally acquired HBV infection was documented in 1% of infants for whom HBsAg test results were available. Nearly 95% of these infants had received HBV vaccine and HBIG within 12 hours of birth. (44) Younger maternal age, HBeAg positivity, high maternal viral load ( ‡2,000 IU/mL), and infant receipt of fewer than 3 HBV vaccines were associated with increased risk of infection. Children infected perinatally are infectious for years, but despite often profound viremia, they do not exhibit clinical disease, having only mildly elevated alanine aminotransferase values and living as immune-tolerant patients as they transition to states of immune-active/clearance or inactive carrier. Persons who are HBsAg-positive are at risk of HBV reactivation if they receive any type of immunosuppressive therapy. Forty percent of persons receiving immunosuppressive therapy reactivate HBV, with liver failure developing in 13% and a case-fatality of 16%. (45)
Clinical Features
Acute HBV infections can be asymptomatic or symptomatic. Older children, adolescents, and adults are more likely to have symptomatic disease, with 30% to 50% of children older than age 5 years exhibiting symptoms. Nonspecific symptoms such as nausea, malaise, fever, and fatigue may be present. Acute disease, characterized by jaundice, decreased appetite, and emesis, presents after viremia and HBsAg antigenemia have peaked. Fulminant hepatitis can also be observed. Extrahepatic manifestations of HBV infection, such as exanthems, arthralgias-arthritis, cryoglobulinemia, thrombocytopenia, glomerulonephritis, and Gianotti-Crosti syndrome, may also be present with acute infection. Some 95% of mother-to-child transmissions occur during the intrapartum period, with the remainder occurring in utero. Most infected infants lack symptoms. Between 15% and 40% of children who have CHB infection develop cirrhosis and/or hepatic carcinoma, and 25% of those children die from these complications. (41) Viral replication, inflammation, regeneration, and fibrosis associated with cirrhosis are virologic and histopathologic features of chronic infection. Although the precise mechanism by which HBV causes hepatocellular carcinoma is not completely known, a direct oncogenic effect by the virus is suspected. (46)
Diagnostic Testing
The interpretation of diagnostic tests for HBV infection can be challenging. The usual diagnostic serology should include IgG antibody against hepatitis B surface antigen (HBsAb), IgM antibody against hepatitis B core antigen (HBcAb), and HBsAg. Based on these results, clinicians can determine if the child is immune to HBV, has active HBV infection, is in the "window period" for HBV infection, or is immune following vaccination (Table 2, Figs 1 and 2) . The "window period" is defined as the time from the onset of infection to the development of serologic evidence of infection. The diagnosis of HBV infection is made by serum detection of HBsAg. Antigenemia persists in carriers, but integrated viral genome can reactivate in certain circumstances. Hepatitis B surface antibodies result from infection and vaccination, but hepatitis B core IgG antibody can only result from infection and not vaccination because the vaccine lacks the core antigen. (47) Among those who clear the infection, HBsAg is no longer detectable after 6 months. It is important to remember that vaccination may lead to the detection of antigenemia. (48)(49) The use of antiviral agents in late pregnancy has been shown to reduce mother-to-child transmission. (54) Prevention Screening all pregnant women at the first prenatal visit captures nearly all infected mothers. However, supplemental testing during the third trimester or at the time of delivery is warranted in some women. This is especially important if mothers report additional risk factors, such as injection drug use, having been incarcerated, being a household or sexual contact of a person known to have HBV infection, being from a country with greater than 2% endemicity, or having parents from a country with greater than 8% endemicity. Neonates born to HbsAg-positive mothers should be given both passive and active immunization within 12 hours of birth using HBIG and HBV vaccine (Tables 3 and 4 ). This combination mitigates against vertical transmission for 85% to 95% of infants who are appropriately treated. (55) The course of routine active vaccination against HBV is not altered among these newborns, who should receive 3 doses by age 6 months, with the second dose provided at age 2 months. All other newborns should receive the first dose of the HBV vaccine series before hospital discharge. Screening of exposed infants is best undertaken after age 18 months, once maternal antibodies and immunoglobulin have cleared. (56) Although virus is detectable in the milk of lactating mothers, breastfeeding is not contraindicated as long as the child has received appropriate prophylaxis.
All children, but especially those with CHB, should be vaccinated against HAV (Table 3) .
HEPATITIS C Epidemiology
Like HBV, HCV is enveloped, pro-oncogenic, and noncytotoxic and is most commonly transmitted via exposure to contaminated blood. As a flavivirus, HCV has a genome composed of a single-stranded positive-sense RNA molecule. HCV has 6 distinct genotypes, and mutations generate quasispecies, both of which influence overall response to specific therapy as well as the patient's clinical presentation. Genotype 3 infection is most likely to progress to fibrosis. Unlike HBV, mother-to-child transmission of HCV is extremely uncommon, approaching 5% among the singly infected and reaching w10% among mothers coinfected with HIV. In developed countries, 1% to 2% of mothers are infected with HCV. Globally, however, some 150 million individuals are infected. Among those infected perinatally with HCV, nearly 80% progress to chronic infection, although most are asymptomatic. (39) For patients infected with either HBV or HCV, progression to liver disease is greatly accelerated by the consumption of alcohol. Accordingly, abstinence is most appropriate. Risk factors for acquiring these viruses are similar. Specifically, patients requiring hemodialysis, those who have received a tattoo from an unregulated venue, those who have received an intravenous blood product before July 1992, recreational intravenous and/or nasal drug users, and men who have sex with men are at increased risk for acquiring HCV (Table 1) .
Diagnostic Testing
The detection of anti-HCV IgG antibodies is the primary diagnostic method for acute and past HCV infection ( Table  2) . As for many other infections that can be potentially acquired during pregnancy, the presence of IgG antibodies in young infants born to mothers known to have HCV is not diagnostic because of the presence of transplacentally acquired antibodies. In HCV-exposed infants, clinicians must wait at least until age 18 months before the assay can be useful as a diagnostic test. In young infants in whom it is important to determine the presence of infection, a nucleic acid amplification test (NAAT) such as polymerase chain reaction assay is necessary. No antiviral therapy is indicated pending confirmation of infection.
Rapid diagnostic antibody tests are highly accurate, with high sensitivity and specificity. (57)(58) Although newer antibody detection assays have greater sensitivity and specificity, a large number of HCV-infected persons may experience a window period in which antibody assay results may be falsenegative. Within 3 months of exposure, most infected persons have a positive antibody test. NAAT is used to detect the presence of viremia, to help predict clinical outcomes and need for antiviral therapy, and to determine response to therapy.
Infants born to mothers with HCV infection should be evaluated at age 18 months via both antibody and RNA screening. RNA screening could be undertaken as early as age 2 months, but some who have positive results still clear the infection spontaneously. As with HBV, those infected with HCV in whom therapy is deferred should receive annual serial screening with a-fetoprotein and ultrasonography to monitor progression of fibrosis and development of HCC. Patients who have HCV infection must have immunity against HAV and HBV confirmed and should receive active immunization if not previously vaccinated (Table 3) .
Treatment
The development of effective antiviral regimens for the treatment of chronic HCV infection (CHC) has been a major advance in the fields of hepatology and infectious diseases. Although data on their use in young children are limited, ongoing studies in adolescents and young adults should yield information on which regimens are safer and more effective for use in children with CHC. Perhaps in the near future, therapy can be initiated earlier in the infection before advanced liver disease develops. Historically, use of pegylated interferon-a and ribavirin therapy was limited both by sustained virologic response and adverse effect profile. (56) This combination was only w50% effective in children and adolescents with HCV genotype 1 infection, the most common genotype in the United States. The regimen was more effective in persons with genotype 2 and 3 infections. However, treatment was usually initiated once the person had developed advanced disease. Adverse effects with interferon were not uncommon. Influenzalike symptoms, leukopenia, and anemia could limit completion of treatment regimens.
Costly new direct-acting antivirals (DAAs), such as sofosfubir, telaprevir, and dasabuvir, are used in combination. DAAs target viral protease, polymerase, and NS5A protein necessary for replication and assembly of new viruses. In studies performed in adults, cure was achieved in nearly all patients, whether they had treatment-naïve or refractory CHC, in as few as 12 weeks of therapy based on genotype distinctions. (59) Cure rates of greater than 90% can now be achieved with interferon-free combinations. Various combinations are undergoing clinical trials in children ages 3 to 17 years. The combination of ombitasvir, paritaprevir/ ritonavir, and ribavirin is undergoing trials against genotype 4 HCV, while this combination plus dasabuvir is being studied against genotype 1 disease. (56) Infection is more difficult to manage among those coinfected with different HCV genotypes or with HBV or HIV. Therapy should be directed by hepatology and infectious diseases specialists because patients should be considered for ongoing trials of these newer agents given the adult outcomes to date. New antiviral treatments for HCV consisting of protease inhibitors, sofosbuvir, and ribavirin have demonstrated increased quality-adjusted life-years and reduced deaths in adults. Although cost-effectiveness per person treated is noticeable, the demand for these newer therapies may pose a major financial burden to the health care system as these agents become available. (60) The availability of safe, effective, and less expensive antiviral regimens has the potential to reduce the incidence, morbidity, mortality, and health care expenditures associated with HCV. Such availability also may serve to trigger routine prenatal screening to identify infected mothers and potentially lead to early treatment of mother and infant to prevent CHC. (56) In addition, these agents could be used following an occupational exposure as a strategy to prevent infection. Hepatitis E virus (HEV), transmitted by the fecal-oral route, is recognized as a major cause of morbidity and mortality, especially in pregnant women and immunocompromised hosts. In some regions of the world, HEV may the most common cause of acute hepatitis. (62) HEV is a small, nonenveloped RNA virus within the newly formed Herpesviridae family. Four genotypes have been identified, and genotypes 1 and 2 have been associated with epidemic hepatitis outbreaks after contact with contaminated water. Genotypes 3 and 4 are mostly zoonotic and emerge after contact with domestic and wild pigs. Humans are usually infected after close contact with swine. Infections with HEV are still uncommon in the United States. However, travel to endemic areas poses a risk for acquisition. (63) Clinical features of the disease are similar to those of HAV infection. Chronic infection is usually not the norm in the previously healthy person, but severe disease and death is well described in infected pregnant women and older adults. Chronic disease has been described in immunocompromised individuals. Antiviral therapy consisting of pegylated interferon-a and ribavirin or ribavirin monotherapy has been used to treat persons with chronic infection. (64)(65) The precise efficacy of this regimen is still unknown, with most of the data resulting from case reports and small studies. An effective HEV vaccine has been produced in China. (66) Hepatitis D virus (HDV) causes infection in persons infected with HBV. HDV requires HBV for replication and cannot produce infection in its absence. HDV is distributed worldwide. It can infect the person acutely as a coinfection with acute HBV or in someone who has a chronic HBV infection. The clinical presentation of infection resembles that of HBV, but it may contribute to a more severe presentation aggravated by fulminant hepatitis. Transmission is similar to that for HBV, with most infections resulting from exposure to contaminated body fluids such as blood or blood products, through intravenous drug use, or via sexual contact. The prevention of HBV through vaccination prevents HDV infection.
Prevention
References and CME quiz for this article are at http://pedsinreview.aappublications.org/content/37/10/426.
Summary
• On the basis of strong epidemiologic evidence, hepatitis viruses are responsible for significant morbidity and mortality in young infants and children throughout the world.
(1) (22)(33) • On the basis of research evidence, hepatitis A and B vaccines are effective in preventing disease. Furthermore, data strongly demonstrate that hepatitis A and B vaccines are safe in young infants and children. (23)(24)(26)(34) • On the basis of strong evidence, pregnant mothers should be screened and concomitant active and passive immunization against hepatitis B should be provided to newborns as a strategy to prevent chronic hepatitis B in children. (44)(47) • On the basis of new research, the use of antiviral agents is beneficial in the treatment of and potential clearance of chronic infections caused by hepatitis B and C viruses. (54)(55)(57)(58) Parent Resources from the AAP at HealthyChildren.org
• Hepatitis A: https://www.healthychildren.org/English/health-issues/vaccine-preventable-diseases/Pages/Hepatitis-A.aspx.
• Hepatitis A Vaccine: What You Need to Know (VIS): https://www.healthychildren.org/English/safety-prevention/immunizations/Pages/ Hepatitis-A-Vaccine-What-You-Need-to-Know.aspx.
• Hepatitis B: https://www.healthychildren.org/English/health-issues/vaccine-preventable-diseases/Pages/Hepatitis-B.aspx.
• Hepatitis B Vaccine: What You Need to Know (VIS): https://www.healthychildren.org/English/health-issues/vaccine-preventablediseases/Pages/Hepatitis-B.aspx.
• Hepatitis C: https://www.healthychildren.org/English/health-issues/conditions/abdominal/Pages/Hepatitis-C.aspx.
